The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
fluindione results in decreased activity of VKORC1 protein fluindione inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1]; fluindione inhibits the reaction [VKORC1 protein results in increased reduction of vitamin K1 oxide]
fluindione inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1]; fluindione inhibits the reaction [VKORC1L1 protein results in increased reduction of vitamin K1 oxide] fluindione results in decreased activity of VKORC1L1 protein
[ICI 118551 binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; ICI 118551 binds to and results in decreased activity of ADRB1 protein; ICI 118551 inhibits the reaction [cyanopindolol binds to ADRB1 protein] [Dobutamine co-treated with ICI 118551] results in decreased expression of ADRB1 mRNA; [Dobutamine co-treated with ICI 118551] results in decreased expression of ADRB1 protein; ICI 118551 inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]
[ICI 118551 binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased abundance of Dinoprostone]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] which results in decreased susceptibility to Nicotine; [ICI 118551 co-treated with ADRB2 protein] results in increased expression of GNAS protein; [ICI 118551 co-treated with ADRB2 protein] results in increased expression of GRK2 protein; ICI 118551 binds to and results in decreased activity of ADRB2 protein; ICI 118551 inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein]; ICI 118551 inhibits the reaction [[carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein]; ICI 118551 inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [Albuterol binds to and results in increased activity of ADRB2 protein]; ICI 118551 inhibits the reaction [carvedilol promotes the reaction [ADRB2 protein binds to ARRB2 protein]]; ICI 118551 inhibits the reaction [cyanopindolol binds to ADRB2 protein]; ICI 118551 inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein]; ICI 118551 inhibits the reaction [Formoterol Fumarate affects the expression of ADRB2 mRNA]; ICI 118551 inhibits the reaction [Iodocyanopindolol binds to ADRB2 protein]; ICI 118551 inhibits the reaction [Isoproterenol binds to and results in increased activity of ADRB2 protein]; ICI 118551 inhibits the reaction [olodaterol affects the expression of ADRB2 mRNA]; ICI 118551 inhibits the reaction [Terbutaline binds to and results in increased activity of ADRB2 protein] [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Fenoterol affects the abundance of Norepinephrine]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] which affects the uptake of Levodopa; ICI 118551 binds to and results in decreased activity of ADRB2 protein; ICI 118551 inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in decreased uptake of Levodopa]; ICI 118551 inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Dopamine]; ICI 118551 inhibits the reaction [CGP 12177 binds to ADRB2 protein]; ICI 118551 inhibits the reaction [Iodocyanopindolol binds to ADRB2 protein]; ICI 118551 inhibits the reaction [Terbutaline results in increased activity of ADRB2 protein] ICI 118551 inhibits the reaction [[BRL 37344 binds to and results in increased activity of ADRB2 protein] which results in increased uptake of Glucose]; ICI 118551 inhibits the reaction [[Clenbuterol binds to and results in increased activity of ADRB2 protein] which results in decreased uptake of Glucose]; ICI 118551 inhibits the reaction [ADRB2 results in decreased susceptibility to Histamine]; ICI 118551 inhibits the reaction [Isoproterenol results in increased activity of ADRB2 protein]
[ICI 118551 binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; ICI 118551 binds to and results in decreased activity of ADRB3 protein; ICI 118551 binds to and results in increased activity of ADRB3 protein; ICI 118551 inhibits the reaction [cyanopindolol binds to ADRB3 protein] [Dobutamine co-treated with ICI 118551] results in increased expression of ADRB3 mRNA; [Dobutamine co-treated with ICI 118551] results in increased expression of ADRB3 protein
capsazepine inhibits the reaction [ICI 118551 results in increased secretion of [CALCA protein co-treated with CALCB protein]]; ICI 118551 results in increased secretion of [CALCA protein co-treated with CALCB protein]
capsazepine inhibits the reaction [ICI 118551 results in increased secretion of [CALCA protein co-treated with CALCB protein]]; ICI 118551 results in increased secretion of [CALCA protein co-treated with CALCB protein]
ICI 118551 inhibits the reaction [Isoproterenol results in increased expression of IL18 mRNA]; ICI 118551 inhibits the reaction [Isoproterenol results in increased expression of IL18 protein]
ICI 118551 inhibits the reaction [Isoproterenol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; ICI 118551 inhibits the reaction [Isoproterenol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; ICI 118551 inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA]; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; ICI 118551 inhibits the reaction [Terbutaline promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]
[ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; ICI 118551 inhibits the reaction [[carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein]; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Shiga Toxin results in increased expression of MAPK1 protein]] [Dobutamine co-treated with ICI 118551] results in increased activity of MAPK1 protein; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Lipopolysaccharides results in increased activity of MAPK1 protein]]
[ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; ICI 118551 inhibits the reaction [[carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein]; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Shiga Toxin results in increased expression of MAPK3 protein]] [Dobutamine co-treated with ICI 118551] results in increased activity of MAPK3 protein; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Lipopolysaccharides results in increased activity of MAPK3 protein]]
ICI 118551 results in decreased expression of MMP2 mRNA; ICI 118551 results in decreased expression of MMP2 protein ICI 118551 results in decreased secretion of MMP2 protein
ICI 118551 results in decreased expression of MMP9 mRNA; ICI 118551 results in decreased expression of MMP9 protein ICI 118551 results in decreased secretion of MMP9 protein
ICI 118551 results in decreased expression of PTGS2 mRNA; ICI 118551 results in decreased expression of PTGS2 protein [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2]
ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Shiga Toxin results in increased expression of TNF protein]] ICI 118551 inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; ICI 118551 inhibits the reaction [Isoproterenol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; ICI 118551 inhibits the reaction [Isoproterenol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]
pevonedistat results in increased cleavage of and results in increased activity of CASP3 protein; Tretinoin promotes the reaction [pevonedistat results in increased cleavage of and results in increased activity of CASP3 protein]
pevonedistat results in increased abundance of JUN protein Tretinoin promotes the reaction [pevonedistat results in increased abundance of JUN protein]
pevonedistat results in increased cleavage of PARP1 protein pevonedistat results in increased cleavage of and results in increased activity of PARP1 protein; Tretinoin promotes the reaction [pevonedistat results in increased cleavage of and results in increased activity of PARP1 protein]
pevonedistat results in increased abundance of PMAIP1 protein pevonedistat affects the expression of PMAIP1 mRNA Tretinoin promotes the reaction [pevonedistat results in increased abundance of PMAIP1 protein]
[Phenindione results in decreased activity of NQO1 protein] which results in increased abundance of aristolochic acid I; [Phenindione results in decreased activity of NQO1 protein] which results in increased abundance of aristolochic acid I metabolite
Phenindione results in decreased activity of VKORC1 protein Phenindione inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1]
Phenindione inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1] Phenindione results in decreased activity of VKORC1L1 protein
Sulfasalazine inhibits the reaction [rasagiline results in increased expression of GDNF protein] rasagiline results in increased expression of GDNF mRNA; rasagiline results in increased expression of GDNF protein
rasagiline results in increased localization of and results in increased activity of RELA protein; Sulfasalazine inhibits the reaction [rasagiline results in increased localization of and results in increased activity of RELA protein]